uniQure NV (QURE)
25.28
+0.77
(+3.14%)
USD |
NASDAQ |
Sep 30, 10:15
uniQure EPS Diluted (Quarterly) : -1.224 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.224 |
| March 31, 2026 | -0.8532 |
| December 31, 2025 | -0.5949 |
| September 30, 2025 | -1.376 |
| June 30, 2025 | -0.6882 |
| March 31, 2025 | -0.8216 |
| December 31, 2024 | -1.50 |
| September 30, 2024 | -0.9109 |
| June 30, 2024 | -1.158 |
| March 31, 2024 | -1.356 |
| December 31, 2023 | -1.530 |
| September 30, 2023 | -1.875 |
| June 30, 2023 | -1.437 |
| March 31, 2023 | -1.628 |
| December 31, 2022 | 0.1449 |
| September 30, 2022 | -1.023 |
| June 30, 2022 | -0.837 |
| March 31, 2022 | -1.002 |
| December 31, 2021 | 0.1664 |
| September 30, 2021 | -0.7915 |
| June 30, 2021 | 8.512 |
| March 31, 2021 | -0.914 |
| December 31, 2020 | -0.0156 |
| September 30, 2020 | -1.209 |
| June 30, 2020 | -0.9586 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.6323 |
| December 31, 2019 | -0.9477 |
| September 30, 2019 | -0.5794 |
| June 30, 2019 | -0.8301 |
| March 31, 2019 | -0.7371 |
| December 31, 2018 | -0.586 |
| September 30, 2018 | -0.59 |
| June 30, 2018 | -0.57 |
| March 31, 2018 | -0.59 |
| December 31, 2017 | -0.89 |
| September 30, 2017 | -0.40 |
| June 30, 2017 | -0.83 |
| March 31, 2017 | -0.80 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | -0.61 |
| June 30, 2016 | -0.8694 |
| March 31, 2016 | -0.9923 |
| December 31, 2015 | -0.635 |
| September 30, 2015 | -1.200 |
| June 30, 2015 | -0.9624 |
| March 31, 2015 | -0.7757 |
| December 31, 2014 | -0.7745 |
| September 30, 2014 | -0.6757 |
| June 30, 2014 | -0.6993 |
| March 31, 2014 | -0.7125 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Kymera Therapeutics, Inc. | -0.6235 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Twist Bioscience Corp. | -0.5617 |
| GRAIL, Inc. | -2.557 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -81.06M |
| Revenue (Quarterly) | 5.841M |
| Total Expenses (Quarterly) | 86.90M |
| Enterprise Value | 1.441B |
| Gross Profit Margin (Quarterly) | 10.00% |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -16.01% |
| Normalized Earnings Yield | -15.89 |